Juvéderm® Volbella® XC, Is Now The First And Only Dermal Filler To Receive FDA Approval For Use Under The Eyes
Volbella, one of the dermal fillers in the most popular dermal filler family, Juvederm, has now become FDA-approved for filling hollows and circles under the eyes.
This is the latest news from Allergan Aesthetics, an AbbVie company. Clinical trials have shown that 90% of subjects were satisfied after one year following their treatment with Volbella for under-eye hollows.
VOLBELLA’s approval for under-eye treatment
According to Carrie Strom, President of Global Allergan Aesthetics and Senior Vice President of AbbVie,
"Allergan Aesthetics offers the broadest portfolio of treatment options designed to address the delicate eye area from topical skin care with SkinMedica®, to crow's feet lines with BOTOX® Cosmetic (onabotulinumtoxinA) and now, with this approval, the infraorbital hollows, commonly referred to as tear troughs, with JUVÉDERM® VOLBELLA® XC."
Commonly used around the mouth to smooth lines and wrinkles, and in the lips to achieve supple, plump volume, VOLBELLA has now been FDA approved for an additional indication–the tear troughs under the eyes. The area around the eyes and the under-eye hollows is one of the most common concerns patients have.
A new standard of treatment
Despite the fact that many patients have wanted cosmetic treatment for this area, it hasn’t been available widely until now for a reason. The area around and especially under the eyes is a sensitive area to inject and requires superlative skill and precision. New training for this newly-approved indication for VOLBELLA is a requirement for any practitioner who intends to use this for patients.
AMI trainer, Board Certified Oculofacial Plastic Surgeon and Ophthalmologist, Dr. Julie Woodward considers that this is a milestone in the cosmetic industry, and went on to state,
"The characteristics of JUVÉDERM® VOLBELLA® XC with lower amounts of hyaluronic acid molecules and low water affinity provides a soft, smooth formulation appropriate for treating undereye hollows and I am excited to work with Allergan Aesthetics on a robust injector and patient education plan to ensure safe and effective outcomes in this challenging to treat area. The results of the clinical trial demonstrate significant improvements in the appearance of undereye hollows and overall appearance. In addition, 80% of subjects reported they were a little or not at all bothered by how tired and old the under-eye area looked at 3 months compared to 15% and 30% before treatment, respectively."
Clinical studies show a satisfaction rate of 83.1%, with the majority of subjects experiencing continued improvement for up to one year. 90.1% of patients would recommend the VOLBELLA under-eye treatment to a friend.
In clinical studies, side effects included tenderness, swelling, bruising, swelling, lumpiness, redness, pain, firmness, discoloration, and itching. These side effects were reported to be mild, and the great majority resolved in 30 days. Any that did not were resolved within 45 days.
About Allergan Aesthetics
Allergan Aesthetics is an AbbVie company that develops and manufactures a range of leading aesthetics brands and products, including injectable treatments, body contouring, skin care, and more. The Allergan Aesthetics goal is to consistently provide customers with innovation, education, exceptional service, and a commitment to excellence–all with a personal touch. To learn more, please visit www.AllerganAesthetics.com.